Pharmaceuticals Analysts discuss key takeaways from Sanofi’s (SNY) investigational therapy, Alphamedix, on an Analyst/Industry conference call to be held on November 24.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi Advances with Dupixent and Teizeild Approvals in November 2025
- Sanofi facility in France cited for quality control issues by ANSM
- FDA appoints Richard Pazdur as Director of CDER
- Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer
- Sanofi, Regeneron report all primary endpoints met in LIBERTY-AFRS-AIMS study